Article Contents ::
- 1 Details About Generic Salt :: Bicaluta
- 2 Main Medicine Class::
- 3 (BYE-kah-LOO-tah-mide) Casodex Tablets for oral use 50 mg. Class: Antiandrogen Antineoplastic hormone Indications Advanced prostate cancer in combination with a luteinizing hormone releasing hormone (LHRH) analog. Safety and efficacy not established. Contraindications Standard considerations. Route/Dosage Advanced Prostate Cancer ADULTS: PO 50 mg (1 tablet) once daily at the same time of day with or without food. Interactions Warfarin Prothrombin time may increase when bicalutamide is initiated in patients stabilized on chronic warfarin therapy. Lab Test Interferences Elevated AST, ALT, bilirubin, BUN, and creatinine, and decreased hemoglobin and white cell count. Adverse Reactions CARDIOVASCULAR: Angina pectoris; CHF; hypertension. CNS: Myasthenia; anxiety; depression; confusion; somnolence; nervousness; loss of libido; neuropathy. DERMATOLOGIC: Dry skin; pruritus; alopecia. ENDOCRINE: Hot flashes; gynecomastia; breast pain; diabetes mellitus. GI: Anorexia; dyspepsia; rectal hemorrhage; melena; increased liver function enzymes. GU: Impotence; nocturia; hematuria; reduced sperm count. MUSCULOSKELETAL: Arthritis; myalgia; leg cramps; hypertonia. RESPIRATORY: Increased cough; pharyngitis; bronchitis; pneumonia; rhinitis; lung disorder. Precautions Pregnancy: Category X. Lactation: Bicalutamide is not indicated for use in women. Children: Safety and efficacy not established. Gynecomastia/Breast pain: Reported in patients treated for prostate cancer. Hepatic function impairment: Use bicalutamide with caution in patients with moderate to severe hepatic impairment. Hepatotoxicity: Generally occurred within the first 3 to 4 mo of treatment. Women: Do not be used in women. PATIENT CARE CONSIDERATIONS Administration/Storage Store tablets at controlled room temperature. Initiate therapy simultaneously with the LHRH analog. Bicalutamide may be taken without regard to meals. Assessment/Interventions Measure serum transaminase levels prior to starting treatment at regular intervals for the first 4 mo of treatment, and periodically thereafter. If clinical symptoms or signs suggestive of liver dysfunction occur (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, “flu-like” symptoms, dark urine, jaundice, right upper quadrant tenderness), measure the serum transaminases immediately, in particular the serum ALT. If at any time a patient has jaundice, or their ALT rises > 2 times the upper limit of normal, immediately discontinue bicalutamide, with close follow-up of liver function. Regular assessments of serum Prostate Specific Antigen (PSA) may be helpful in monitoring the patient’s response. Monitor LFTs at baseline and at 3-mo intervals during therapy. Patient/Family Education Notify health care provider if any of the following symptoms occur: nausea, vomiting, abdominal pain, fatigue, anorexia, “flu-like” symptoms, dark urine, jaundice, right upper quadrant tenderness. Bicalutamide and the LHRH analog will be initiated at the same time. Do not interrupt or stop taking these medications without consulting health care provider. Medicscientist Drug Facts
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Bicaluta
Main Medicine Class::
(BYE-kah-LOO-tah-mide)
Casodex
Tablets for oral use
50 mg.
Class: Antiandrogen
Antineoplastic hormone
Indications Advanced prostate cancer in combination with a luteinizing hormone releasing hormone (LHRH) analog. Safety and efficacy not established.
Contraindications Standard considerations.
Route/Dosage
Advanced Prostate Cancer
ADULTS: PO 50 mg (1 tablet) once daily at the same time of day with or without food.
Interactions
Warfarin
Prothrombin time may increase when bicalutamide is initiated in patients stabilized on chronic warfarin therapy.
Lab Test Interferences Elevated AST, ALT, bilirubin, BUN, and creatinine, and decreased hemoglobin and white cell count.
Adverse Reactions
CARDIOVASCULAR: Angina pectoris; CHF; hypertension. CNS: Myasthenia; anxiety; depression; confusion; somnolence; nervousness; loss of libido; neuropathy. DERMATOLOGIC: Dry skin; pruritus; alopecia. ENDOCRINE: Hot flashes; gynecomastia; breast pain; diabetes mellitus. GI: Anorexia; dyspepsia; rectal hemorrhage; melena; increased liver function enzymes. GU: Impotence; nocturia; hematuria; reduced sperm count. MUSCULOSKELETAL: Arthritis; myalgia; leg cramps; hypertonia. RESPIRATORY: Increased cough; pharyngitis; bronchitis; pneumonia; rhinitis; lung disorder.
Precautions
Pregnancy: Category X. Lactation: Bicalutamide is not indicated for use in women. Children: Safety and efficacy not established. Gynecomastia/Breast pain: Reported in patients treated for prostate cancer. Hepatic function impairment: Use bicalutamide with caution in patients with moderate to severe hepatic impairment. Hepatotoxicity: Generally occurred within the first 3 to 4 mo of treatment. Women: Do not be used in women.
PATIENT CARE CONSIDERATIONS
Administration/Storage
- Store tablets at controlled room temperature.
- Initiate therapy simultaneously with the LHRH analog. Bicalutamide may be taken without regard to meals.
Assessment/Interventions
- Measure serum transaminase levels prior to starting treatment at regular intervals for the first 4 mo of treatment, and periodically thereafter. If clinical symptoms or signs suggestive of liver dysfunction occur (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, “flu-like” symptoms, dark urine, jaundice, right upper quadrant tenderness), measure the serum transaminases immediately, in particular the serum ALT. If at any time a patient has jaundice, or their ALT rises > 2 times the upper limit of normal, immediately discontinue bicalutamide, with close follow-up of liver function.
- Regular assessments of serum Prostate Specific Antigen (PSA) may be helpful in monitoring the patient’s response.
- Monitor LFTs at baseline and at 3-mo intervals during therapy.
Patient/Family Education
- Notify health care provider if any of the following symptoms occur: nausea, vomiting, abdominal pain, fatigue, anorexia, “flu-like” symptoms, dark urine, jaundice, right upper quadrant tenderness.
- Bicalutamide and the LHRH analog will be initiated at the same time. Do not interrupt or stop taking these medications without consulting health care provider.
Medicscientist Drug Facts
PATIENT CARE CONSIDERATIONS
Drugs Class ::
(BYE-kah-LOO-tah-mide) |
Casodex |
Tablets for oral use |
50 mg. |
Class: Antiandrogen |
Antineoplastic hormone |
Indications for Drugs ::
Indications Advanced prostate cancer in combination with a luteinizing hormone releasing hormone (LHRH) analog. Safety and efficacy not established.
Drug Dose ::
Route/Dosage
Advanced Prostate Cancer
ADULTS: PO 50 mg (1 tablet) once daily at the same time of day with or without food.
Contraindication ::
Contraindications Standard considerations.
Drug Precautions ::
Precautions
Pregnancy: Category X. Lactation: Bicalutamide is not indicated for use in women. Children: Safety and efficacy not established. Gynecomastia/Breast pain: Reported in patients treated for prostate cancer. Hepatic function impairment: Use bicalutamide with caution in patients with moderate to severe hepatic impairment. Hepatotoxicity: Generally occurred within the first 3 to 4 mo of treatment. Women: Do not be used in women.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CARDIOVASCULAR: Angina pectoris; CHF; hypertension. CNS: Myasthenia; anxiety; depression; confusion; somnolence; nervousness; loss of libido; neuropathy. DERMATOLOGIC: Dry skin; pruritus; alopecia. ENDOCRINE: Hot flashes; gynecomastia; breast pain; diabetes mellitus. GI: Anorexia; dyspepsia; rectal hemorrhage; melena; increased liver function enzymes. GU: Impotence; nocturia; hematuria; reduced sperm count. MUSCULOSKELETAL: Arthritis; myalgia; leg cramps; hypertonia. RESPIRATORY: Increased cough; pharyngitis; bronchitis; pneumonia; rhinitis; lung disorder.
Drug Mode of Action ::
(BYE-kah-LOO-tah-mide) |
Casodex |
Tablets for oral use |
50 mg. |
Class: Antiandrogen |
Antineoplastic hormone |
Drug Interactions ::
Interactions
Warfarin
Prothrombin time may increase when bicalutamide is initiated in patients stabilized on chronic warfarin therapy.
Drug Assesment ::
Assessment/Interventions
- Measure serum transaminase levels prior to starting treatment at regular intervals for the first 4 mo of treatment, and periodically thereafter. If clinical symptoms or signs suggestive of liver dysfunction occur (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, “flu-like” symptoms, dark urine, jaundice, right upper quadrant tenderness), measure the serum transaminases immediately, in particular the serum ALT. If at any time a patient has jaundice, or their ALT rises > 2 times the upper limit of normal, immediately discontinue bicalutamide, with close follow-up of liver function.
- Regular assessments of serum Prostate Specific Antigen (PSA) may be helpful in monitoring the patient’s response.
- Monitor LFTs at baseline and at 3-mo intervals during therapy.
Drug Storage/Management ::
Administration/Storage
- Store tablets at controlled room temperature.
- Initiate therapy simultaneously with the LHRH analog. Bicalutamide may be taken without regard to meals.
Drug Notes ::
Patient/Family Education
- Notify health care provider if any of the following symptoms occur: nausea, vomiting, abdominal pain, fatigue, anorexia, “flu-like” symptoms, dark urine, jaundice, right upper quadrant tenderness.
- Bicalutamide and the LHRH analog will be initiated at the same time. Do not interrupt or stop taking these medications without consulting health care provider.
Medicscientist Drug Facts